STOCK TITAN

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)

UroGen Pharma (Nasdaq: URGN) announced FDA acceptance of its New Drug Application (NDA) for UGN-102, an investigational drug for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA set a PDUFA goal date of June 13, 2025. If approved, UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC.

The NDA is supported by data from three clinical trials, including the ENVISION trial, which met its primary endpoint with a 79.6% complete response rate at three months. The trial also showed an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved a complete response at 3 months. Common adverse events included dysuria, hematuria, and urinary tract infection.

UroGen's CEO, Liz Barrett, emphasized the potential of UGN-102 to expand treatment options for LG-IR-NMIBC patients, addressing unmet needs in this space.

UroGen Pharma (Nasdaq: URGN) ha annunciato l'accettazione da parte della FDA della sua Richiesta di Nuovo Farmaco (NDA) per UGN-102, un farmaco in fase di investigazione per il carcinoma della vescica non muscolare invasivo a basso grado e rischio intermedio (LG-IR-NMIBC). La FDA ha stabilito una data obiettivo PDUFA del 13 giugno 2025. Se approvato, UGN-102 sarebbe il primo farmaco approvato dalla FDA per il LG-IR-NMIBC.

La NDA è supportata da dati provenienti da tre studi clinici, incluso lo studio ENVISION, che ha raggiunto il suo obiettivo primario con un tasso di risposta completa del 79,6% a tre mesi. Lo studio ha inoltre mostrato una durata della risposta di 12 mesi del 82,3% secondo la stima di Kaplan-Meier nei pazienti che hanno raggiunto una risposta completa a 3 mesi. Gli eventi avversi comuni includevano disuria, ematuria e infezione delle vie urinarie.

Il CEO di UroGen, Liz Barrett, ha sottolineato il potenziale di UGN-102 per ampliare le opzioni di trattamento per i pazienti con LG-IR-NMIBC, affrontando le esigenze insoddisfatte in questo campo.

UroGen Pharma (Nasdaq: URGN) anunció la aceptación por parte de la FDA de su Solicitud de Nuevo Medicamento (NDA) para UGN-102, un fármaco en investigación para el cáncer de vejiga no invasivo muscular de bajo grado y riesgo intermedio (LG-IR-NMIBC). La FDA estableció una fecha objetivo PDUFA del 13 de junio de 2025. Si se aprueba, UGN-102 sería el primer medicamento aprobado por la FDA para LG-IR-NMIBC.

La NDA está respaldada por datos de tres ensayos clínicos, incluido el ensayo ENVISION, que cumplió con su objetivo primario con una tasa de respuesta completa del 79,6% a los tres meses. El ensayo también mostró una duración de respuesta de 12 meses del 82,3% según la estimación de Kaplan-Meier en pacientes que lograron una respuesta completa a los 3 meses. Los eventos adversos comunes incluyeron disuria, hematuria e infección del tracto urinario.

La CEO de UroGen, Liz Barrett, enfatizó el potencial de UGN-102 para ampliar las opciones de tratamiento para los pacientes con LG-IR-NMIBC, abordando las necesidades no satisfechas en este ámbito.

UroGen Pharma (Nasdaq: URGN)는 저급 중간 위험 비근육 침범 방광암(LG-IR-NMIBC)을 위한 시험 약물 UGN-102에 대한 새로운 약물 신청(NDA)의 FDA 수용을 발표했습니다. FDA는 2025년 6월 13일로 PDUFA 목표 날짜를 설정했습니다. 승인될 경우, UGN-102는 LG-IR-NMIBC에 대한 FDA 승인 약물의 첫 번째가 될 것입니다.

NDA는 ENVISION 시험을 포함하여 세 가지 임상 시험의 데이터로 지원됩니다. 이 시험은 3개월 시점에서 79.6%의 완전 반응률로 주요 목표를 달성했습니다. 또한 이 시험은 3개월에서 완전 반응을 이룬 환자에서 Kaplan-Meier 추정 방식으로 12개월 반응 지속 기간이 82.3%임을 보여주었습니다. 일반적인 부작용으로는 배뇨통, 혈뇨, 요로 감염 등이 포함되었습니다.

UroGen의 CEO인 Liz Barrett는 LG-IR-NMIBC 환자를 위한 치료 옵션을 확장하는 UGN-102의 잠재력을 강조하며 이 분야의 충족되지 않은 니즈를 다루고 있습니다.

UroGen Pharma (Nasdaq: URGN) a annoncé l'acceptation par la FDA de sa demande de nouveau médicament (NDA) pour UGN-102, un médicament expérimental pour le cancer de la vessie non invasif musculaire à faible degré et à risque intermédiaire (LG-IR-NMIBC). La FDA a fixé une date limite PDUFA au 13 juin 2025. Si approuvé, UGN-102 serait le premier médicament approuvé par la FDA pour le LG-IR-NMIBC.

La NDA est soutenue par des données provenant de trois essais cliniques, y compris l'essai ENVISION, qui a atteint son objectif principal avec un taux de réponse complet de 79,6% à trois mois. L'essai a également montré une durée de réponse de 12 mois de 82,3% selon l'estimation de Kaplan-Meier chez les patients ayant obtenu une réponse complète à 3 mois. Les événements indésirables courants comprenaient la dysurie, l'hématurie et les infections des voies urinaires.

La CEO d'UroGen, Liz Barrett, a souligné le potentiel de l'UGN-102 pour élargir les options de traitement pour les patients atteints de LG-IR-NMIBC, en répondant à des besoins non satisfaits dans ce domaine.

UroGen Pharma (Nasdaq: URGN) gab die Annahme seines Antrags auf Zulassung eines neuen Arzneimittels (NDA) durch die FDA für UGN-102 bekannt, ein experimentelles Arzneimittel für niedriggradigen intermediären Risiko nicht muskelinvasiven Blasenkrebs (LG-IR-NMIBC). Die FDA setzte ein PDUFA-Zieldatum für den 13. Juni 2025. Wenn genehmigt, wäre UGN-102 das erste von der FDA genehmigte Medikament für LG-IR-NMIBC.

Die NDA wird durch Daten aus drei klinischen Studien unterstützt, darunter die ENVISION-Studie, die ihr primäres Ziel mit einer 79,6% vollständigen Ansprechrate nach drei Monaten erfüllt hat. Die Studie zeigte auch eine Reaktionsdauer von 12 Monaten von 82,3% nach der Kaplan-Meier-Schätzung bei Patienten, die nach 3 Monaten eine vollständige Antwort erzielt hatten. Zu den häufigen unerwünschten Ereignissen gehörten Dysurie, Hämaturie und Harnwegsinfektionen.

UroGens CEO Liz Barrett betonte das Potenzial von UGN-102 zur Erweiterung der Behandlungsoptionen für Patienten mit LG-IR-NMIBC und zur Behebung der unbefriedigten Bedürfnisse in diesem Bereich.

Positive
  • FDA acceptance of New Drug Application for UGN-102
  • Potential to be the first FDA-approved medicine for LG-IR-NMIBC
  • 79.6% complete response rate at three months in ENVISION trial
  • 82.3% 12-month duration of response in patients with complete response at 3 months
  • Robust data set from three clinical trials supporting the NDA
Negative
  • PDUFA goal date set for June 13, 2025, indicating a long wait for potential approval
  • Common adverse events reported in clinical trials

Insights

The FDA's acceptance of UroGen's New Drug Application (NDA) for UGN-102 is a significant milestone in the treatment landscape for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This development is particularly noteworthy as UGN-102 could become the first FDA-approved medicine specifically for this condition.

The PDUFA date of June 13, 2025, sets a clear timeline for potential market entry. The robust clinical data supporting the NDA is impressive, with a 79.6% complete response rate at three months and an 82.3% 12-month duration of response in the ENVISION trial. These efficacy results, coupled with a manageable safety profile, suggest that UGN-102 could offer a valuable new treatment option for patients.

For investors, this development represents a potential near-term catalyst for UroGen Pharma. If approved, UGN-102 could capture a significant market share in the LG-IR-NMIBC space, given the current lack of FDA-approved treatments. However, it's important to note the extended timeline to the PDUFA date, which may impact short-term stock performance.

The FDA acceptance of UroGen's NDA for UGN-102 is a positive development for the company's financial outlook. With a market cap of $502,479,815, UroGen is positioning itself to potentially capture a significant portion of the LG-IR-NMIBC market, which could substantially boost revenues if UGN-102 is approved in 2025.

Investors should consider the following financial implications:

  • Potential for increased valuation leading up to the PDUFA date
  • Possible partnerships or licensing deals to maximize market penetration
  • Increased R&D expenses as the company prepares for potential commercialization
  • The need for capital to support launch preparations and marketing efforts

While the long-term outlook appears promising, the extended timeline to potential approval means that UroGen will need to carefully manage its cash runway. Investors should monitor the company's burn rate and any potential capital raises in the interim period. The unique position of UGN-102 as a potential first-in-class treatment could provide significant upside if approved, but also carries the inherent risks associated with regulatory decisions.

  • PDUFA goal date set for June 13, 2025
  • UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 13, 2025.

"The FDA acceptance of our NDA is a pivotal moment in our journey to bring UGN-102 to patients,” said Liz Barrett, President and Chief Executive Officer of UroGen. “UGN-102 could be the first FDA-approved medicine for LG-IR-NMIBC, offering a novel approach that could expand treatment options and address unmet needs. There is an urgent need for innovative solutions in this space, and we are dedicated to collaborating with the FDA as we prepare for a potential launch of UGN-102 in 2025.”

Dr. Mark Schoenberg, Chief Medical Officer of UroGen, stated, “The NDA for UGN-102 is backed by a robust data set demonstrating impressive durability of response across three clinical trials and a favorable safety profile. Notably, the ENVISION trial successfully met its primary endpoint, showing a 79.6% complete response rate at three months after the first instillation of UGN-102. Additionally, the latest results from that trial revealed an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved a complete response at 3 months. The most common treatment-emergent adverse events in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. Additionally, the safety profile observed in the ENVISION trial was consistent with that seen in other studies of UGN-102. We believe that, if approved, UGN-102’s ability to achieve durable complete responses and potentially reduce recurrence rates while extending treatment-free intervals will represent a significant advance in managing LG-IR-NMIBC.”

About UGN-102

UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently under regulatory review for approval in the treatment of LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. An NDA for UGN-102 is currently under review by the FDA with a potential decision expected by June 13, 2025. The U.S. market for LG-IR-NMIBC that UGN-102 can address, if approved, is valued at approximately $5 billion.

About ENVISION

The Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as primary chemoablative therapy in patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at the three-month assessment after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550).

About Non-Muscle Invasive Bladder Cancer (NMIBC)

In the U.S. bladder cancer is the second most common urologic cancer in men. LG-IR-NMIBC represents approximately 22,000 newly diagnosed bladder cancer patients each year and an estimated 60,000 recurrences annually among patients diagnosed from previous years. Bladder cancer primarily affects older populations with the median age of diagnosis 73 years and an increased risk of comorbidities. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 to be the first FDA-approved medicine for LG-IR-NMIBC; the potential patient benefits and opportunities for UGN-102, if approved; the potential timing for a decision from the FDA on the UGN-102 NDA; the estimated size of the U.S. market that could be addressed by UGN-102, if approved; the potential launch timing for UGN-102, if approved; the potential for UGN-102 to achieve durable complete responses and reduce recurrence rates while extending treatment-free intervals; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs; and the potential of UroGen’s sustained release technology to make local delivery more effective as compared to other treatment options. Words such as “anticipate,” “can,” “expect,” “if,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-102 has been accepted by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the PDUFA goal date may be delayed due to various factors outside UroGen’s control; past results are not necessarily indicative of results that may be seen in the future, including in larger patient populations; the ability to obtain and maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q quarter ended June 30, 2024, filed with the SEC on August 13, 2024 (which is available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@UroGen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@UroGen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

What is the PDUFA goal date for UroGen's UGN-102 NDA?

The FDA has set a PDUFA goal date of June 13, 2025 for UroGen's UGN-102 New Drug Application.

What condition is UGN-102 designed to treat?

UGN-102 is designed to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

What was the complete response rate in the ENVISION trial for UGN-102?

The ENVISION trial for UGN-102 showed a 79.6% complete response rate at three months after the first instillation.

What was the 12-month duration of response for UGN-102 in the ENVISION trial?

The ENVISION trial revealed an 82.3% 12-month duration of response by Kaplan-Meier estimate in patients who achieved a complete response at 3 months.

What are the most common side effects of UGN-102 reported in the ENVISION trial?

The most common side effects of UGN-102 in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention.

UroGen Pharma Ltd. Ordinary Shares

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Stock Data

504.92M
37.83M
9.18%
85.27%
15.67%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RA'ANANA